BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
6589 results:

  • 1. Complete remission in a pretreated, microsatellite-stable,
    He L; Li H; Wang Y; Li W; Gao L; Xu B; Hu J; He P; Pu W; Sun G; Wang Z; Han Q; Liu B; Chen H
    Front Immunol; 2024; 15():1354613. PubMed ID: 38617840
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Decoding the Versatile Landscape of Autophagic Protein VMP1 in cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
    Renna FJ; Gonzalez CD; Vaccaro MI
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Epidemiological and clinicopathological features of kras, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
    Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
    Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. SG-Transunet: A segmentation-guided Transformer U-Net model for kras gene mutation status identification in colorectal cancer.
    Ma Y; Guo Y; Cui W; Liu J; Li Y; Wang Y; Qiang Y
    Comput Biol Med; 2024 May; 173():108293. PubMed ID: 38574528
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
    Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
    [No Abstract]    [Full Text] [Related]  

  • 6. Targeting
    Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Concurrent kras p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report.
    Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
    Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
    Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
    J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Circular RNAs in the kras pathway: Emerging players in cancer progression.
    Hussain MS; Moglad E; Afzal M; Bansal P; Kaur H; Deorari M; Ali H; Shahwan M; Hassan Almalki W; Kazmi I; Alzarea SI; Singh SK; Dua K; Gupta G
    Pathol Res Pract; 2024 Apr; 256():155259. PubMed ID: 38503004
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Noninvasive Stratification of Colon cancer by Multiplex PET Imaging.
    Malviya G; Lannagan TRM; Johnson E; Mackintosh A; Bielik R; Peters A; Soloviev D; Brown G; Jackstadt R; Nixon C; Gilroy K; Campbell A; Sansom OJ; Lewis DY
    Clin Cancer Res; 2024 Apr; 30(8):1518-1529. PubMed ID: 38493804
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic colorectal cancer: A Multicenter Retrospective Comparative Study.
    Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
    JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Impact of kras mutation on the tumor microenvironment in colorectal cancer.
    Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
    Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Gluing GAP to RAS Mutants: A New Approach to an Old Problem in cancer Drug Development.
    Ranđelović I; Nyíri K; Koppány G; Baranyi M; Tóvári J; Kigyós A; Tímár J; Vértessy BG; Grolmusz V
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473821
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Impact of kras
    Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
    ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
    Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
    Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy.
    Qian C; Yang W; Li M; Feng Y; Dai N; Luo H; Jian D; Li X; Yang Y; He Y; Wang D; Li C; Xiao H
    Eur J Surg Oncol; 2024 Apr; 50(4):108242. PubMed ID: 38460248
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Oncogenic mutations of kras modulate its turnover by the CUL3/LZTR1 E3 ligase complex.
    Damianou A; Liang Z; Lassen F; Vendrell I; Vere G; Hester S; Charles PD; Pinto-Fernandez A; Santos A; Fischer R; Kessler BM
    Life Sci Alliance; 2024 May; 7(5):. PubMed ID: 38453365
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Twelve-month progression-free survival with sotorasib and panitumumab in kras G12C mutant metastatic colorectal cancer.
    Kavgaci G; Dizdar O; Yalcin S
    Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by kras mutation status.
    Shaykevich A; Chae D; Silverman I; Bassali J; Louloueian N; Siegman A; Bandyopadhyaya G; Goel S; Maitra R
    Invest New Drugs; 2024 Apr; 42(2):229-239. PubMed ID: 38446332
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 330.